The Lynx Group
Cholangiocarcinoma News

Conversations on Cholangiocarcinoma

Managing Adverse Events in CCA Patients Treated with FGFR Inhibitors

Considering Toxicities Associated with Specific and Pan-FGFR Inhibitors
Videos — April 21, 2021
Drs Javle, Báñales, and Hollebecque describe their thoughts about the use of pan-FGFR inhibitors compared with those that primarily target FGFR2 and the potential of treating CCA with inhibitors of FGFR1, 3, and 4. Moreover, they consider the most common adverse events associated with inhibitors of FGFR2, of which the most difficult to manage are hyperphosphatemia, nail toxicity, eye toxicity, and fatigue. The importance of educating oncologists on how to treat these toxicities is key to maintaining dose intensity of FGFR inhibitors.
Read More

Selecting Among the FGFR Inhibitors in FGFR2 Fusion–Positive Cholangiocarcinoma

The Role of FGFR Inhibitors in Treating FGFR2 Fusion–Positive Cholangiocarcinoma
Videos — February 22, 2021
Drs Javle and Hollebecque review the phase 2 clinical trial efficacy data of pemigatinib, infigratinib, and futibatinib as second-line therapy of FGFR2 fusion–positive cholangiocarcinoma, and explore use of these agents in the first-line and adjuvant settings.
Read More

The Role of FGFR Genetic Alterations in Cholangiocarcinoma
Videos — January 21, 2021
A discussion of the molecular biology of the FGFR pathway in the growth and development of cholangiocarcinoma.
Read More

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: